Mivebresib (ABBV-075) is primarily investigated for its potential in cancer treatment, particularly in targeting various types of malignancies. It functions as a BET (Bromodomain and Extra-Terminal) protein inhibitor, which plays a critical role in regulating gene expression. By inhibiting BET proteins, it disrupts the transcription of genes involved in cancer cell growth and survival. This mechanism makes it a promising candidate for treating hematologic cancers such as acute myeloid leukemia (AML) and multiple myeloma, as well as solid tumors like prostate cancer. Clinical trials are ongoing to evaluate its efficacy and safety, either as a monotherapy or in combination with other anticancer agents. Its ability to target epigenetic pathways offers a novel approach to overcoming resistance to conventional therapies.